Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/32208
Title: Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus
Authors: Chonlatip Pipattanaboon
Tadahiro Sasaki
Mitsuhiro Nishimura
Chayanee Setthapramote
Pannamthip Pitaksajjakul
Pornsawan Leaungwutiwong
Kriengsak Limkittikul
Orapim Puiprom
Mikiko Sasayama
Panjaporn Chaichana
Tamaki Okabayashi
Takeshi Kurosu
Ken ichiro Ono
Pongrama Ramasoota
Kazuyoshi Ikuta
Mahidol University
Osaka University
Department of Microbiology and Immunology
Mahidol-Osaka Center for Infectious Diseases
Medical & Biological Laboratories Co, Ltd
Japan International Cooperation Agency
Keywords: Medicine
Issue Date: 14-Aug-2013
Citation: Biologics: Targets and Therapy. Vol.7, No.1 (2013), 175-187
Abstract: Background: Hybridomas that produce human monoclonal antibodies (HuMAbs) against Dengue virus (DV) had been prepared previously using peripheral blood lymphocytes from patients with DV during the acute and convalescent phases of a secondary infection. Anti-DV envelope glycoprotein (E) 99 clones, anti-DV premembrane protein (prM) 8 clones, and antiDV nonstructural protein 1 (NS1) 4 clones were derived from four acute-phase patients, and anti-DV E 2 clones, anti-DV prM 2 clones, and anti-DV NS1 8 clones were derived from five convalescent-phase patients. Methods and results: In the present study, we examined whether these clones cross-reacted with Japanese encephalitis virus (JEV), which belongs to the same virus family. Forty-six of the above-described 99 (46/99) anti-E, 0/8 anti-prM, and 2/4 anti-NS1 HuMAbs from acutephase, and 0/2 anti-E, 0/2 anti-prM, and 5/8 anti-NS1 HuMAbs from convalescent-phase showed neutralizing activity against JEV. Thus, most of the anti-E and anti-NS1 (but not the anti-prM) antibodies cross-reacted with JEV and neutralized this virus. Interestingly, 3/46 anti-E HuMAbs derived from acute-phase patients and 3/5 anti-NS1 HuMAbs from convalescent-phase patients showed particularly high neutralizing activity against JEV. Consequently, the HuMAbs showing neutralization against JEV mostly consisted of two populations: one was HuMAbs recognizing DV E and showing neutralization activity against all four DV serotypes (complex-type) and the other was HuMAbs recognizing DV NS1 and showing subcomplex-type cross-reaction with DV. Conclusion: Anti-DV E from acute phase (46/99) and anti-DV NS1 (7/12) indicate neutralizing activity against JEV. In particular, three of 46 anti-DV E clones from acute phase and three of five anti-NS1 clones from convalescent phase showed strong neutralizing activity against JEV. © 2013 Pipattanaboon et al, publisher and licensee Dove Medical Press Ltd.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84882611859&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/32208
ISSN: 11775491
11775475
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.